CH

Chemed Corporation

CHEHealthcareNASDAQ

Medical Care Facilities

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$2.53B
+4.1% YoY
Net Income
$265.2M
-12.2% YoY
EBITDA
$422.4M
-9.0% YoY
Free Cash Flow
$307.9M

Scan Results

Daily timeframe
DateIndicatorDetails
Oct 19▲ MACD Positive CrossoverHistogram +1.6425, positive momentum
Oct 17▲ MACD Positive CrossoverHistogram +1.6425, positive momentum
About Chemed Corporation

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, doctors, registered nurses, home health aides, social workers, clergy, and volunteers. The company carries a $6.70B market cap, placing it firmly in the mid-cap category. The company operates through two segments: VITAS and Roto-Rooter segments.

Where CHE stands vs its 150-day and 200-day moving averages

As of the October 19, 2026 close, CHE finished 10.31% above its 150-day moving average ($464.50) and 11.88% above its 200-day moving average ($457.96). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is CHE overbought or oversold?

At the October 19, 2026 close, CHE's RSI(14) was 48.2, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$6.70B
P/E (TTM)25.80
Fwd P/E18.64
EPS$19.88
Beta0.51
52W Change+17.4%
Dividend Yield0.55%
ROE27.1%
Analysis

On the balance sheet, CHE has $40.2M in cash with $294.8M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company generates $307.9M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 27.1% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 13.5% further supports the picture of efficient asset utilization. Revenue has been uneven over recent years, ranging from $2.14B to $2.53B.

With a beta below 0.7, Chemed Corporation typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. No single metric tells the full story. Reviewing CHE's risk profile alongside its fundamentals and technical indicators provides a more complete picture.

Links
More Healthcare stocks
Browse all stocks →
⚠Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms